oxybutynin has been researched along with Acquired Meningomyelocele in 18 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravesical oxybutynin hydrochloride was administered to 17 patients with a neuropathic bladder (myelomeningocele in 15 and spinal cord tumour in two) and urinary incontinence refractory to intermittent catheterisation." | 3.69 | Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. ( Chiba, K; Kaneko, S; Miyata, M; Mizunaga, M; Yachiku, S, 1994) |
| " 21/32 patients became totally continent with the dosage (A)." | 2.69 | Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. ( Dörsam, J; Gerner, HJ; Haferkamp, A; Staehler, G, 2000) |
| "Propiverine was better tolerated than oxybutynin, having fewer adverse drug reactions (9." | 1.35 | Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Domurath, B; Henne, T; Körner, I; Madersbacher, H; Mürtz, G; Niedeggen, A; Nounla, J; Pannek, J; Schulte-Baukloh, H; Schultz-Lampel, D; Strugala, G, 2009) |
| "The study comprised 225 children with a neurogenic bladder from MMC who were evaluated with urodynamic testing and voiding cysto-urethrography to identify those at high risk of upper tract damage." | 1.31 | Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. ( D'Aleo, CM; Ferrara, P; Salvaggio, E; Salvatore, S; Tarquini, E, 2001) |
| "The etiologies and forms of congenital neuropathic bladder are described: contractile (25%), acontractile (15%), and intermediate (60%)." | 1.31 | Assessment and conservative management of the neuropathic bladder. ( Rickwood, AM, 2002) |
| "Forty-one MMC children with detrusor hyperreflexia (19 boys and 22 girls, aged 2 months to 15 years; mean 4." | 1.30 | Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. ( Fiedler, U; Goessl, C; Härle, B; Knispel, HH; Miller, K; Steffen-Wilke, K, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 11 (61.11) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Madersbacher, H | 1 |
| Mürtz, G | 1 |
| Alloussi, S | 1 |
| Domurath, B | 1 |
| Henne, T | 1 |
| Körner, I | 1 |
| Niedeggen, A | 1 |
| Nounla, J | 1 |
| Pannek, J | 1 |
| Schulte-Baukloh, H | 1 |
| Schultz-Lampel, D | 1 |
| Bock, P | 1 |
| Strugala, G | 1 |
| Aslan, AR | 1 |
| Kogan, BA | 2 |
| Almodhen, F | 1 |
| Capolicchio, JP | 1 |
| Jednak, R | 1 |
| El Sherbiny, M | 1 |
| Purcell, MH | 1 |
| Gregory, JG | 1 |
| Zerin, JM | 1 |
| DiPietro, MA | 1 |
| Ritchey, ML | 1 |
| Bloom, DA | 1 |
| Hernandez, RD | 1 |
| Hurwitz, RS | 1 |
| Foote, JE | 1 |
| Zimmern, PE | 1 |
| Leach, GE | 1 |
| Mizunaga, M | 1 |
| Miyata, M | 1 |
| Kaneko, S | 1 |
| Yachiku, S | 1 |
| Chiba, K | 1 |
| Connor, JP | 1 |
| Betrus, G | 1 |
| Fleming, P | 1 |
| Perlmutter, AD | 1 |
| Reitelman, C | 1 |
| Von Zweigbergk, M | 1 |
| Nordin, B | 1 |
| Jonsson, S | 1 |
| Palmer, LS | 1 |
| Zebold, K | 1 |
| Firlit, CF | 1 |
| Kaplan, WE | 1 |
| Goessl, C | 1 |
| Knispel, HH | 1 |
| Fiedler, U | 1 |
| Härle, B | 1 |
| Steffen-Wilke, K | 1 |
| Miller, K | 1 |
| Kaefer, M | 1 |
| Pabby, A | 1 |
| Kelly, M | 1 |
| Darbey, M | 1 |
| Bauer, SB | 1 |
| Haferkamp, A | 1 |
| Staehler, G | 1 |
| Gerner, HJ | 1 |
| Dörsam, J | 1 |
| Ferrara, P | 1 |
| D'Aleo, CM | 1 |
| Tarquini, E | 1 |
| Salvatore, S | 1 |
| Salvaggio, E | 1 |
| Rickwood, AM | 1 |
| Lin-Dyken, DC | 1 |
| Wolraich, ML | 1 |
| Hawtrey, CE | 1 |
| Doja, MS | 1 |
| Belloli, G | 1 |
| Campobasso, P | 1 |
| Mercurella, A | 1 |
| Baskin, LS | 1 |
| Benard, F | 1 |
1 review available for oxybutynin and Acquired Meningomyelocele
| Article | Year |
|---|---|
Conservative management in neurogenic bladder dysfunction.
Topics: Anti-Dyskinesia Agents; Benzhydryl Compounds; Biofeedback, Psychology; Botulinum Toxins; Child; Chil | 2002 |
2 trials available for oxybutynin and Acquired Meningomyelocele
| Article | Year |
|---|---|
Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Hydronephrosis; Infant; Kidney; Male; Mandelic | 1994 |
Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Topics: Administration, Intravesical; Adolescent; Adult; Child; Child, Preschool; Cholinergic Antagonists; C | 2000 |
15 other studies available for oxybutynin and Acquired Meningomyelocele
| Article | Year |
|---|---|
Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Epidemiologic Methods; Female; Humans; Infant; Male | 2009 |
Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
Topics: Adolescent; Child; Cholinergic Antagonists; Female; Follow-Up Studies; Humans; Hydronephrosis; Kidne | 2007 |
Intermittent catheterization: evaluation of complete dryness and independence in children with myelomeningocele.
Topics: Adolescent; Adult; Bacteriuria; Child; Child, Preschool; Combined Modality Therapy; Epinephrine; Eva | 1984 |
Intravesical oxybutinin chloride in children with intermittent catheterization: sonographic findings.
Topics: Administration, Intravesical; Child; Female; Humans; Male; Mandelic Acids; Meningomyelocele; Parasym | 1994 |
Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids; Meningomyelocele; | 1994 |
Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients.
Topics: Administration, Intravesical; Adolescent; Adult; Child; Child, Preschool; Female; Follow-Up Studies; | 1994 |
[Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Female; | 1996 |
Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
Topics: Administration, Intravesical; Child; Child, Preschool; Cholinergic Antagonists; Humans; Mandelic Aci | 1997 |
Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Female; Follow-U | 1998 |
Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele.
Topics: Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Female; Follow-Up Studies; Humans; Inf | 1999 |
Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.
Topics: Administration, Intravesical; Administration, Oral; Child; Child, Preschool; Cholinergic Antagonists | 2001 |
Assessment and conservative management of the neuropathic bladder.
Topics: Benzhydryl Compounds; Child; Child, Preschool; Cholinergic Antagonists; Cresols; Female; Humans; Inf | 2002 |
Follow-up of clean intermittent catheterization for children with neurogenic bladders.
Topics: Adolescent; Child; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Meningomyelocele; Parasy | 1992 |
Neuropathic urinary incontinence in pediatric patients: management with artificial sphincter.
Topics: Adolescent; Adult; Female; Humans; Male; Mandelic Acids; Meningomyelocele; Parasympatholytics; Treat | 1992 |
Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation.
Topics: Combined Modality Therapy; Female; Humans; Infant, Newborn; Male; Mandelic Acids; Meningomyelocele; | 1990 |